Astrocytes play a number of key functions in health and disease. Reactivation of astrocytes occurs in most, if not all, neurological diseases. Most current information on the mechanisms underlying astrogliosis derives from studies using rodent experimental systems, mainly because the ability to study human astrocytes under healthy and pathological conditions has been hampered by the difficulty in obtaining primary human astrocytes. Here we describe robust and reliable derivation of astrocytes from human induced pluripotent stem cells (iPSCs). Phenotypically characterized human iPSC-derived astrocytes exhibit typical traits of physiological astrocytes, including spontaneous and induced calcium transients. Moreover, human iPSC-derived astrocytes respond to stimulation with a pro-inflammatory combination of tumor necrosis factor alpha, interleukin 1alpha, and complement component C1q by undergoing changes in gene expression patterns suggesting acquisition of a reactive astrocyte phenotype. Together, these findings provide evidence suggesting that human iPSC-derived astrocytes are a suitable experimental model system to study astrocyte function and reactivation in healthy and pathological conditions of the human nervous system.
INTRODUCTION
Astrocytes play a number of important roles in the healthy nervous system by supporting neuronal activity in several ways, including regulation of synaptic transmission, release of neurotrophic factors, promotion of neuronal metabolic functions, and cross-talk with other glial cells, to name only a few [reviewed by Zhou et al., 2019; Zuchero and Barres, 2015] . Astrocytes are also important players in the injured or diseased nervous system, when they can acquire 'reactive' phenotypes, characterized by morphological and gene expression changes during a process often termed astrogliosis [reviewed by Liddelow and Barres, 2017; Siracusa et al., 2019; Valori et al., 2019] . Reactive astrocytes mediate a variety of mechanisms, including release of cytokines and chemokines that can participate in complex neuroinflammatory processes, intercellular communication with microglia involved in immune responses, and modulation of immune cell activation at damaged sites. Reactive astrocytes are thought to contribute to either neuroprotective or neuroinflammatory responses depending on the local microenvironment, although evidence exists that astrogliosis is often a complex process characterized by a combination of both inflammatory and protective effects depending on the stage of the damage or injury process [Li et al., 2019; Liddelow and Barres, 2017; Yamanaka and Komine, 2018] .
Astrocyte reactivation is a common event in virtually all neurological diseases [Li et al., 2019; Liddelow and Barres, 2017; Siracusa et al., 2019; Yamanaka and Komine, 2018] . For instance, hallmarks of astrocyte activation feature prominently in post-mortem tissues from amyotrophic lateral sclerosis (ALS) patients, as well as in the spinal cord and cranial motor nuclei in ALS transgenic mouse models [Anneser et al., 2004; Baron et al., 2005; Evans et al., 2014; Ferraiuolo et al., 2007; Poloni et al., 2000; Schiffer et al., 1996] . More importantly, increasing evidence suggests that reactive astrocytes contribute directly to the degeneration of motor circuits in ALS animal models by promoting non-cell autonomous mechanisms of motor neuron degeneration [Diaz-Amarilla et al., 2011; Ferraiuolo, 2014; Haidet-Phillips et al., 2011; Ouali Alami et al., 2018; Radford et al., 2015; Yamanaka and Komine, 2018] .
Progress in understanding how astrocytes contribute to human neurological diseases has been slow, at least in part due to the fact that most information on the mechanisms underlying astrogliosis has emerged from studies with rodent experimental model systems. There is evidence that rodent and human astrocytes exhibit a number of gene expression and functional differences suggesting that rodent astrocytes may not always represent informative model systems for human astrocytes, especially in neurodegenerative conditions [Oberheim et al., 2009; Tarassishin et al., 2014; Zhang et al., 2016] . Moreover, the paucity of studies based on human primary astrocytes has limited the ability to study human astrocytes carrying the genetic alterations found in familial form of neurodegenerative diseases, thus affecting the goal of complementing studies using experimental animal models with human cell-based models. This situation has recently started to change due to progress in the application of induced pluripotent stem cell (iPSC) technologies in the generation of human iPSC-derived astrocytes [Serio et al., 2013; Shaltouki et al., 2013; Tcw et al., 2017] . This remarkable progress offers previously unavailable experimental opportunities to study human astrocyte biology, model astrocyte pathophysiological mechanisms in vitro, and design large-scale screens of new potential therapeutic compounds targeting astrocytes.
Here we describe the generation and phenotypic characterization of astrocytes derived from human iPSCs, and show that these human iPSC-derived astrocytes display molecular and biological features typical of physiological astrocytes. In particular, human iPSC-derived astrocytes respond to astrogliosis-inducing conditions by undergoing changes in gene expression patterns suggestive of a transition to a reactive phenotype. These findings suggest that human iPSC-derived astrocytes represent physiologically-informative experimental model systems to study astrocyte function and reactivation in healthy and diseased conditions of the human nervous system.
METHODS

Human iPSC lines
Human iPSC line NCRM-1 (male) was obtained from the National Institutes of Health Stem Cell Resource (Bethesda, MD, USA). AJG-001-C4 control iPSC line was established from peripheral blood mononuclear cells (PBMC) obtained from a 37-year-old male through episomal reprogramming. AIW-002-02 iPSC line was established from PBMC obtained from a 37-year-old male through retrovirus reprogramming. These procedures were conducted under Ethical Review Board approval by McGill University. Both AJG 001-C4 and AIW-002-2 iPSC lines were generated at the Montreal Neurological Institute through the Open Biorepository, C-BIGR, under an Open Science framework. Pluripotent state of human iPSC lines was routinely assessed by testing for expression of the stem cell markers NANOG and OCT4. Waltham, MA, USA; Cat. No. 08-774-552) until they reached 70%-80% confluence. At this time point (designated as day in vitro 0 -DIV0), the culture medium was removed, cells were rinsed with phosphate-buffered saline (PBS) (5 ml) and detached by addition of 'Gentle Dissociation Reagent' (3 ml) (STEMCELL Technologies; Cat. No. 07174) stored at room temperature. After 3-5 minutes in Gentle Dissociation Reagent, cells were recovered and transferred to a 15-ml Falcon tube (Corning; Corning, NY, USA; Cat. No. 352070). Dulbecco's minimum essential medium (DMEM)/F12 medium (Life Technologies; 10565-018) was added (7 ml), followed by centrifugation at 1,300 rpm for 3 min. Cell pellets were resuspended in mTeSR medium (1 ml) and transferred into 6-well plates coated with Matrigel. Cells were seeded at 15%-25% confluence and cultured in mTeSR medium (2 ml (Life Technologies; Cat. No. 15140-122) ]. This culture medium was changed (2.5 ml) every two days and cells were cultured until DIV4, when cells received fresh medium (5 ml) and were cultured until they reached confluence (usually by DIV7).
Derivation of neural progenitor cells from human iPSCs
At DIV7, Neural Induction Medium 1 was replaced with 5 ml of 'Neural Induction Medium 2' (DMEM/F12 medium supplemented with 1% N2, 2% B27, 0.1% BSA, 1 mM GlutaMax, 1% nonessential amino acids, 1 µg/ml laminin, 50 U/ml penicillin G, 50 mg/ml streptomycin). Medium was replaced every day until DIV12, when cells were dissociated by incubation with Accutase (Innovative Cell Technologies; San Diego, CA, USA; Cat. No. AT-104) at 37 o C for 3-5 min and transferred to either Petri dishes or 'low attachment' dishes (Fisher Scientific; Cat. No.
FB0875712), followed by culture in 'Neural Progenitor Cell (NPC) Expansion Medium'
[DMEM/F12 medium supplemented with 1% N2, 2% B27, 20 ng/ml EGF (PeproTech; Cat. No.
AF-100-15), 20 ng/ml FGF2 (PeproTech; Cat. No. 450-18b), 1 mM GlutaMax, 1% non-essential amino acids, 1 µg/ml laminin, 50 U/ml penicillin G, 50 mg/ml streptomycin] in the presence of Rock inhibitor Y-27632. Cells were then cultured until formation of free-floating cellular spheres ('neurospheres'), which usually occurred in 2 to 3 days.
In each differentiation procedure, neurospheres were collected using a 40 µm Nylon mesh cell strainer (Corning; Cat. No. 352340) placed over a 50-ml Falcon tube. Cells recovered on cell strainer were rinsed with PBS (5 ml) and then transferred to a 10-cm Matrigel-coated culture dish by flushing with 10 ml NPC Expansion Medium. Another cycle of neurosphere formation and isolation was usually performed by repeating the same steps in order to increase the number of NPCs obtained. On average, ~90% of induced cells were positive for the expression of NPC markers SOX1, SOX2, and PAX6. NPCs obtained following this protocol can be frozen and stored in liquid nitrogen, with usually good cell survival rates upon thawing.
Differentiation of astrocytes from human iPSC-derived neural progenitor cells
Induced human NPCs were differentiated into astrocytes essentially as described previously [Tcw et al., 2017] , with minor modifications. In each derivation, NPCs were seeded at low cell density (15,000 cells/cm 2 ) in two T25 flasks in the presence of 5 ml of NPC expansion medium containing Rock inhibitor. The following day, medium was replaced with 'Astrocyte replaced with fresh medium every 3 to 4 days and cells were maintained under these culture conditions for 30 days without passaging. On average, at least 75% of induced cells were positive for the expression of astrocytes markers, such as S100beta (S100b), connexin 43, and aquaporin 4 (AQ4) after 30 days. At this stage, induced astrocytes were proliferative and were either cultured further or frozen and stored in liquid nitrogen for future use. For the purpose of continued culture, induced astrocytes were switched to 'Astrocyte Differentiation Medium 2' (same as Astrocyte Differentiation Medium 1 but lacking FBS) after 30 days and then cultured under these conditions for 2-3 months, depending on the experimental endpoints. Induced astrocytes were routinely examined for the expression of GFAP, S100b, and AQ4.
Characterization of human iPSC-derived cells by immunocytochemistry
Cultured human iPSCs, induced NPCs and astrocytes were analyzed by immunocytochemistry, which was performed as described previously [Methot et al., 2018] . The following primary antibodies were used: rabbit anti-NANOG (1:500; Abcam; Cambridge, UK; Cat. No. Ab21624); goat anti-OCT3/4 (1:500; Santa Cruz Biotechnology; Dallas, TX; Cat. No. Sc-8628); goat anti-SOX1 (1/500; R&D Systems; Minneapolis, MN, USA; Cat. No. AF3369); goat anti-SOX2 (1/500; R&D Systems, Cat. No. AF2018); rabbit anti-PAX6 (1/500; Covance; Emeryville, CA, USA; Cat.
No. PRB-278P); mouse anti-NESTIN (1/500; Millipore; Cat. No. MAB5326); mouse anti-glial fibrillary acid protein (GFAP) (1/1,000; Sigma-Aldrich, St. Louis, MO, USA; Cat. No. G3893); mouse anti-S100b (1/1,000; Sigma-Aldrich; Cat. No. S2532); rabbit anti-AQ4 (1:500; Sigma-Aldrich; Cat. No. HPA014784). Secondary antibodies against primary reagents raised in various species were conjugated to Alexa Fluor 555, Alexa Fluor 488, or Alexa Fluor 350 (1/1,000, Invitrogen; Burlington, ON, Canada). Images were acquired with a Zeiss Axio Observer Z1 Inverted Microscope using 20X magnification and a ZEISS Axiocam 506 mono camera.
Detection of calcium transients in human iPSC-derived astrocytes
Sixty days after the start of the differentiation protocol, human iPSC-derived astrocytes were incubated with the calcium indicator Fluo-4 AM (1µM; ThermoFisher Scientific; Carlsbad, CA;
Cat. No. F14201) for 30 minutes, followed by two rinsing steps with ScienCell Astrocyte Growth Medium (Cat. No. 1801b), supplemented with antibiotics, for 10 min each. Time-lapse microscopy was then performed at 0.5 Hz with a Zeiss Axio Observer Z1 Inverted Microscope using 20X magnification and a ZEISS Axiocam 506 mono camera. Temperature (37°C), humidity and CO 2 (5%) were maintained constant throughout the course of the experiments through TempModule S and CO 2 moduleS devices (PeCon GmbH; Erbach, Germany). LED 488 nm was set at 20% and exposure time was 200 ms to avoid phototoxicity. For spontaneous calcium wave acquisition, recording was conducted for 5 min and focus stabilisation was achieved with the use of Zeiss Definite focus every 30 images. For induced calcium wave acquisition, recording was performed for 1 min, before the addition of either 10µM glutamate or 10µM ATP, followed by recording for an additional 4 min.
Treatment of human iPSC-derived astrocytes with TNFa a, IL-1a a, and C1q
Sixty days after the start of the differentiation protocol, human iPSC-derived astrocytes were incubated with tumour necrosis factor alpha (TNFa) (30 ng/ml; Cell Sciences; Newburyport, MA; GFAP, Hs00909233_m1; ACTB Hs01060665_g1; GAPDH Hs02786624_g1). Primers/probesets used were obtained from ThermoFisher Scientific. Data were normalized with beta-actin and GAPDH. Relative quantification (RQ) was estimated according to the ∆∆Ct method [Schmittgen and Livak, 2008] .
RESULTS
In vitro generation and molecular characterization of neural progenitor cells from human iPSCs
Neural induction of human iPSCs (three different lines were used) was stimulated by inhibiting TGF-b/BMP-4 signaling using SB431542 compound in combination with Noggin as described in the Methods section. Neuralized cells were tested for the expression of NPC markers, including NESTIN, SOX1, SOX2, and PAX6, 7-14 days after the start of neural induction (DIV 7-14). The majority of neuralized cells expressed these NPC markers at DIV14 (Figure 1) . In contrast, little or no expression of the stem cell markers NANOG and OCT-4 was detected at DIV14 (Supplemental Figure S1 ). These results provide evidence of robust generation of induced cells with features of NPCs from the different human iPSC lines used in these in vitro studies.
In vitro differentiation and molecular characterization of astrocytes from human iPSCs
Astroglial differentiation of human iPSC-derived NPCs was promoted by exposure to a defined astrocyte medium from ScienCell, as previously described [Tcw et al., 2017] , and as detailed in the Methods section. Under these culture conditions, induced cells exhibiting morphological and immunological features of astrocytes were already detectable at DIV30 ( Figure S2 ). At DIV60, many induced cells (~70%-75% on average) were positive for the expression of both S100b and GFAP, two classical markers of astrocyte identity (Figure 2A ). Induced cells also expressed additional astrocyte-enriched proteins/genes, including the gap junction protein connexin 43 ( Figure 2B) , and the genes VIMENTIN, GLUTAMINE SYNTHETASE (GLUL), and EXCITATORY AMINO ACID TRANSPORTER 1 (EAAT1/ SLC1A3/GLAST) ( Figure 2C ). Expression levels of these genes varied between astrocytes derived from different human iPSC lines (cf. Figures 2 and  4 below). At DIV90, human iPSC-derived astroglial cells exhibited mainly flattened morphologies, which included star-shaped cells ( Figure 2D ). Together, these findings show robust generation of induced cells from human iPSCs with molecular and morphological traits typical of astrocytes in vitro.
Human iPSC-derived astrocytes display spontaneous, ATP-induced and glutamateinduced calcium waves
Cytoplasmic Ca 2+ level fluctuations represent a key component of astrocytic intercellular signaling [Shigetomi et al., 2016] . To determine whether human iPSC-derived astrocytes would exhibit spontaneous and/or induced calcium transients, DIV60 astrocytes were incubated with the Ca 2+ indicator, Fluo-4 AM, in the absence (spontaneous Ca 2+ transients) or presence of pulses of extracellular glutamate (10 µM) or ATP (10 µM) (induced Ca 2+ transients). Human iPSC-derived astrocytes displayed spontaneous calcium spikes, suggestive of intercellular signaling among interconnected cells ( Figure 3A) . Moreover, a single application of either glutamate or ATP resulted in calcium wave responses (Figures 3B, C) . Together, these results provide evidence that human iPSC-derived astrocytes display calcium transients in vitro similar to those exhibited by physiological astrocytes, suggesting further that human iPSCs can serve as sources of biologicallyrelevant human astrocytes.
Human iPSC-derived astrocytes acquire a reactive phenotype after exposure to tumor necrosis factor alpha, interleukin 1-alpha and complement C1q
Previous studies have shown that primary rodent brain astrocytes respond to exposure to a combination of TNFa, IL-1a, and C1q by upregulating the expression of several genes associated with an 'A1-type' reactive astrocyte phenotype [Clarke et al., 2018; Liddelow et al., 2017] . To determine whether human iPSC-derived astrocytes would respond in a similar manner to treatment with TNFa, IL-1a and C1q, we exposed DIV60 astrocytes to these factors for 24 hours, followed by analysis of gene expression by real time RT-PCR. These studies showed that transcripts previously associated with an A1-type reactive astrocyte phenotype in rodent cells, such as SERGLYCIN and SERPING1, were upregulated in human iPSC-derived astrocytes (Figure 4A, B) .
Moreover, treatment with TNFa, IL-1a, and C1q led to increased levels of two genes, EAAT1 and GLUL, previously shown to be induced in reactive astrocytes (Bellaver et al., 2017; Beschorner et al., 2007) (Fig. 4C-D) . Consistent with these findings, treated human iPSC-derived astrocytes also displayed increased levels of neuroinflammatory cytokine-encoding transcripts, such as TNFa and IL-1b ( Figure 4E, F) . Based on these results, we examined further whether TNFa/IL-1a/C1qstimulated human iPSC-derived astrocytes would display a pro-inflammatory phenotype by monitoring the levels of transcripts encoding intermediate filament proteins, such as GFAP and VIMENTIN, which are usually upregulated in pro-inflammatory reactive astrocytes (Clarke et al., 2018; Liddelow et al., 2017; Zamanian et al., 2012) . Unexpectedly, neither of these transcripts was increased, rather levels were either decreased or not obviously affected ( Figure 4G, H) . Similar results were obtained in astrocytes derived from different human iPSC lines ( Figure S3 ). Taken together, these findings provide evidence that human iPSC-induced astrocytes respond to exposure to inflammatory conditions by acquiring a mixed reactive phenotype. These results in turn imply that human iPSC-derived astrocytes may provide an informative experimental model system to study the roles of astrocytes in health and disease.
DISCUSSION
Numerous studies are providing increasing evidence that neuronal degeneration in a number of neurodegenerative diseases is not only driven by cell-autonomous mechanisms of neuronal death, but is also promoted by non-cell autonomous processes underlying communication between neuronal and glial cells, including astrocytes [Li et al., 2019; Liddelow and Barres, 2017; Siracusa et al., 2019; Yamanaka and Komine, 2018] .
A documented example of astrocyte involvement in neurodegeneration is provided by ALS,
where an abnormal activation of astrocytes was initially suggested from the analysis of postmortem tissues, cerebrospinal fluids and blood samples from ALS patients [Schiffer et al., 1996; Anneser et al., 2004; Baron et al., 2005; Poloni et al., 2000] . In agreement with these observations, marked neuroinflammation was observed in the spinal cord and cranial motor nuclei of ALS transgenic mouse models [Schiffer et al., 1996; Ferraiuolo et al., 2007; Evans et al., 2014] .
Furthermore, several independent studies, based mainly on in vitro cultures of neural cells derived from ALS transgenic mice, provide evidence suggesting that astrocytes harbouring mutated superoxide dismutase 1 are toxic to primary, as well as pluripotent stem cell-derived, motor neurons, but not to other neuronal populations [Di Giorgio et al., 2008; Marchetto et al., 2008; Nagai et al., 2007] .
It is hypothesized that astrocytes may exert deleterious effects on motor neurons in ALS as a consequence of either gain of toxic functions or loss of supportive functions (or a combination of both). Examples of gain-of-function effects include transmission of mutated proteins such as superoxide dismutase 1, production of reactive oxygen species causing motor neuron hyperexcitability and degeneration, inhibition of autophagy mechanisms in motor neurons, and transmission of extracellular vesicle-transported toxic microRNA species, to name only a few [Fritz at al., 2014; Rojas et al., 2015; Tripathi et al., 2017; Varcianna et al., 2019; Yamanaka and Komine, 2018] .
Progress in understanding the roles of astrocytes in neurological diseases has been hampered by the limited availability of primary human astrocyte cultures, the limited viability of primary cultures of human astrocytes, as well as the observation that rodent and human astrocytes differ at both transcriptional and functional levels, which suggest that the rodent astrocyte models studied to date may not always represent optimal systems for understanding the pathobiology of human astrocytes [Oberheim et al., 2009; Tarassishin et al., 2014; Zhang et al., 2016] . This situation has recently started to change thanks to the increasing availability of human iPSC-based protocols to achieve robust and reliable generation of human astrocytes [e.g., Serio et al., 2013; Shaltouki et al., 2013; Tcw et al., 2017] . Progress in this field of research now offers previously unavailable human experimental model systems to study the biological functions of human astrocyte biology, as well as to model astrocyte pathophysiological mechanisms in vitro. Moreover, human iPSCderived astrocytes have the potential to provide informative platforms for large-scale screens of new potential therapeutic compounds targeting astrocyte-mediated neurotoxic mechanisms.
In the present studies, we have described the derivation and characterization of astrocytes from a number of different human iPSC lines and have provided evidence that these cells display molecular and biological properties resembling those of physiological astrocytes. In particular, human iPSC-derived astrocytes can respond to stimulation with a pro-inflammatory combination of TNFa, IL-1a, and C1q, which are secreted by activated microglia during neuroinflammatory processes and can lead to astrocyte activation [Liddelow et al., 2017] , by upregulating the levels of a number of transcripts encoding molecules previously associated with a reactive astrocyte phenotype. Interestingly, elevated levels of genes previously associated with neurotoxic reactive astrocytes, such as SERGLYCIN, SERPING1, GLUL and TNFa [Bellaver et al., 2017; Fernandes et al., 2016; Liddelow et al., 2017] is not accompanied by a concurrent increase in the levels of transcripts encoding intermediate filament proteins like GFAP and VIMENTIN. Increased levels of GFAP and VIMENTIN are considered a typical feature of pro-inflammatory reactive astrocytes (Clarke et al., 2018; Liddelow et al., 2017; Zamanian et al., 2012) . This situation was correlated with increased levels of EAAT1, encoding a glutamate transporter upregulated in reactive astrocytes with a predicted neuroprotective phenotype [Berschorner et al., 2007] . Together, these findings show a multifaceted pattern of gene expression changes in human iPSC-derived astrocytes exposed to inflammatory molecules under serum-free conditions, suggesting that human iPSCderived astrocytes may provide informative experimental model systems to study the complex biological changes underlying reactive astrogliosis.
The derivation and characterization of human iPSC-derived astrocytes will facilitate the study of the properties and functions of different types of human astrocytes, leading to progress in our understanding of human astrocyte biology. Moreover, they will provide previously unavailable disease-relevant human experimental models to study neurological diseases. In turn, deeply phenotyped disease-relevant astrocytes may provide new experimental model systems to develop cellular assays that may contribute to early-stage drug discovery efforts benefitting neurological and mental health conditions. 
